Precision Neuroscience announced that it has closed a US$250 million Series D, bringing its company-reported total raised since 2021 to US$430 million. Pershing Square Inc., the Ackman Oxman Institute and an unnamed life-sciences investment fund co-led the round.
Precision says the proceeds will expand its clinical program, advance Layer 7 through further FDA review and build commercialization infrastructure. Precision’s intended thought-controlled assistive BCI remains investigational and unavailable for sale in the United States. FDA decision summary, K242618, Precision website.
Wealthy investors and sovereign-linked funding
Named co-leads include Pershing Square Inc. and the Ackman Oxman Institute. Bill Ackman is Pershing Square’s CEO and an Institute co-founder. Duquesne Family Office, Stanley Druckenmiller’s investment firm, also participated.
Another participant, Mubadala Capital, is an asset-management subsidiary of Mubadala Investment Company, the sovereign investor owned by the Government of Abu Dhabi in the United Arab Emirates. Mubadala Capital also manages money for outside investors. The announcement does not identify how much of its Precision investment represents government capital
Which backers have invested in other BCI companies?
| Precision investor | Disclosed Precision investment | Other BCI investments |
|---|---|---|
| re.Mind Capital, co-founded by Christian Angermayer | Participated in the 2023 Series B round. (biospace.com) | Led Blackrock Neurotech’s 2021 financing; also lists Synchron and headset maker OpenBCI in its portfolio. (re.Mind Capital) |
| ARK Invest | Named in the September 2026 round. (globenewswire.com) | Its ARK Venture Fund disclosed a Neuralink holding in May 2026. (ark-funds.com) |
Most of the leading BCI companies from Neuralink to Paradromics have received investments from members of the billionaire class and Gulf state-backed investment funds.
This pattern of capital divesment raises major concerns on the future of BCI control and patient’s rights.
Sources
Undated webpages accessed September 26, 2026.
- US$250 million financing announcement — Precision Neuroscience, GlobeNewswire, September 24, 2026.
- US$102 million financing announcement — Precision Neuroscience, reproduced by Venture Capital Access Online, December 16, 2024.
- Mubadala Capital: subsidiary profile — Mubadala Investment Company, undated.
- About Mubadala — Mubadala Investment Company, undated.
- US$41 million financing announcement — Precision Neuroscience, reproduced by BioSpace, January 25, 2023.
- Portfolio and team — re.Mind Capital, undated.
- US$10 million financing announcement — Blackrock Neurotech, May 19, 2021.
- How To Invest In Neuralink — ARK Funds, May 28, 2026; holdings dated April 30, 2026.
- Layer 7-T clearance letter and summary, K242618 — FDA, March 30, 2025.
- Product website and investigational-device disclaimer — Precision Neuroscience, undated.
- Company updates: financing announcement — Precision Neuroscience, LinkedIn, undated page; used for the discrepancy flagged below.
Leave a Reply